Engineered HCMV‐infected APCs enable the identification of new immunodominant HLA‐restricted epitopes of anti‐HCMV T‐cell immunity.

Authors: Santamorena, Maria Michela¹ (AUTHOR), Tischer‐Zimmermann, Sabine¹ (AUTHOR), Bonifacius, Agnes^1,2 (AUTHOR), Mireisz, Chiara Noemi‐Marie³ (AUTHOR), Costa, Bibiana⁴ (AUTHOR), Khan, Fawad⁵ (AUTHOR), Kulkarni, Upasana⁵ (AUTHOR), Lauruschkat, Chris David⁶ (AUTHOR), Sampaio, Kerstin Laib⁷ (AUTHOR), Stripecke, Renata^8,9 (AUTHOR), Blasczyk, Rainer¹ (AUTHOR), Maecker‐Kolhoff, Britta^2,9,10 (AUTHOR), Kraus, Sabrina⁶ (AUTHOR), Schlosser, Andreas³ (AUTHOR), Cicin‐Sain, Luka^2,5,11 (AUTHOR), Kalinke, Ulrich^4,11 (AUTHOR), Eiz‐Vesper, Britta^1,2 (AUTHOR) eiz-vesper.britta@mh-hannover.de

Source: HLA: Immune Response Genetics. Jun2024, Vol. 103 Issue 6, p1-27. 27p.

Subject Terms: *T cells, *EPITOPES, *CYTOTOXIC T cells, *IMMUNOLOGIC memory, *IMMUNITY, *ALLELES, *DENDRITIC cells

In Vitro Profiling of Commonly Used Post-transplant Immunosuppressants Reveals Distinct Impact on Antiviral T-cell Immunity Towards CMV.

Authors: Krueger, Markus Benedikt, Bonifacius, Agnes, Dragon, Anna Christina, Santamorena, Maria Michela, Nashan, Björn, Taubert, Richard, Kalinke, Ulrich, Maecker-Kolhoff, Britta, Blasczyk, Rainer, Eiz-Vesper, Britta

Source: Transplant International; 2024, p1-13, 13p

Subject Terms: EVEROLIMUS, RAPAMYCIN, T cells, HEMATOPOIETIC stem cells, IMMUNOSUPPRESSIVE agents, IMMUNOLOGIC memory

Reinforcement of cell-mediated immunity driven by tumorassociated Epstein-Barr virus (EBV)-specific T cells during targeted B-cell therapy with rituximab.

Authors: Tischer-Zimmermann, Sabine, Bonifacius, Agnes, Santamorena, Maria Michela, Mausberg, Philip, Stoll, Sven, Döring, Marius, Kalinke, Ulrich, Blasczyk, Rainer, Maecker-Kolhoff, Britta, Eiz-Vesper, Britta

Source: Frontiers in Immunology; 3/24/2023, Vol. 14, p1-18, 18p

Subject Terms: RITUXIMAB, T cells, HISTOCOMPATIBILITY class I antigens, T helper cells, CELLULAR immunity, ANTIGEN presenting cells, EPSTEIN-Barr virus